Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters

Show full item record



Permalink

http://hdl.handle.net/10138/298295

Citation

Vuorio , A & Kovanen , P T 2018 , ' Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters ' , Nutrients , vol. 10 , no. 12 , 1842 . https://doi.org/10.3390/nu10121842

Title: Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
Author: Vuorio, Alpo; Kovanen, Petri T.
Contributor: University of Helsinki, Department of Forensic Medicine
University of Helsinki, Wihuri Research Institute
Date: 2018-12
Language: eng
Number of pages: 10
Belongs to series: Nutrients
ISSN: 2072-6643
URI: http://hdl.handle.net/10138/298295
Abstract: This review covers the current knowledge about plant stanol esters as a dietary treatment option for heterozygous familial hypercholesterolemia (he-FH) children. The current estimation of the prevalence of he-FH is about one out of 200-250 persons. In this autosomal dominant disease, the concentration of plasma low-density lipoprotein cholesterol (LDL-C) is strongly elevated since birth. Quantitative coronary angiography among he-FH patients has revealed that stenosing atherosclerotic plaques start to develop in he-FH males in their twenties and in he-FH females in their thirties, and that the magnitude of the plaque burden predicts future coronary events. The cumulative exposure of coronary arteries to the lifelong LDL-C elevation can be estimated by calculating the LDL-C burden (LDL-C level x years), and it can also be used to demonstrate the usefulness of dietary stanol ester treatment. Thus, when compared with untreated he-FH patients, the LDL-C burden of using statin from the age of 10 is 15% less, and if he-FH patients starts to use dietary stanol from six years onwards and a combination of statin and dietary stanol from 10 years onwards, the LDL-C burden is 21% less compared to non-treated he-FH patients. We consider dietary stanol treatment of he-FH children as a part of the LDL-C-lowering treatment package as safe and cost-effective, and particularly applicable for the family-centered care of the entire he-FH families.
Subject: phytosterol
stanol
diet
familial hypercholesterolemia
coronary heart disease
hypercholesterolemia
children
family
atherosclerosis
low-density cholesterol
PHYTOSTEROLS/-STANOLS
GENERAL-POPULATION
SERUM-CHOLESTEROL
FUNCTIONAL FOODS
POSITION PAPER
HEART-DISEASE
NORTH KARELIA
STEROL
MANAGEMENT
DIAGNOSIS
3143 Nutrition
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
nutrients_10_01842.pdf 887.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record